Vertex Pharmaceuticals Inc / Ma: Pay

Vertex Pharmaceuticals Inc / Ma paid its 6 named executives $59.8M in total in FY2025 (Dec). CEO Reshma Kewalramani was paid $21.1M of that.

Pay$100 in the stock at the end of FY20 → $192
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Reshma KewalramaniCEO and President
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Stuart A. ArbuckleEVP & Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Charles F. Wagner, Jr.EVP & Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Nia TatsisEVP & Chief Regulatory and Quality Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Amit SachdevEVP & Chief Patient and External Affairs Officer
FY2025 (Dec)
1 year
Carmen BozicEVP & Chief Medical Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 8 peers with pay on file was $21.2M. The CEO of Vertex Pharmaceuticals Inc / Ma was paid $21.5M, 1% above the median.

  1. 1Eli Lilly & Co
  2. 2Amgen
  3. 3Biogen
  4. 4Gilead Sciences
  5. 5Vertex Pharmaceuticals Inc / Ma
  6. 6Bristol Myers Squibb
  7. 7AbbVie
  8. 8Incyte
  9. 9Regeneron Pharmaceuticals
  10. 10Alnylam PharmaceuticalsNot disclosed
  11. 11BioMarin Pharmaceuticals, Inc.Not disclosed
  12. 12Jazz Pharmaceuticals plcNot disclosed
  13. 13ModernaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.